Toxic Adenoma natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 3: Line 3:
{{CMG}} ; {{AE}} {{ADG}}
{{CMG}} ; {{AE}} {{ADG}}
==Overview==
==Overview==
If left untreated, some of the patients with toxic adenoma may progress to develop [[thyrotoxicosis]] which increases the risks of [[atrial fibrillation]], [[heart failure]], and decreased bone mineral density in postmenopausal women ([[osteoporosis]]). Common complications of toxic adenoma include [[atrial fibrillation]], neck compression, bone mineral loss, [[thyroid storm]], I-131-related [[hypothyroidism]]. [[Prognosis]] of toxic adenoma is generally good with treatment. About 45% to 75% of patients stay [[euthyroid]] following [[Iodine-131|I-131 therapy]].
If left untreated, some of the patients with toxic adenoma may progress to develop [[thyrotoxicosis]] which increases the risks of [[atrial fibrillation]], [[heart failure]], and decreased [[bone mineral density]] in [[postmenopausal]] women ([[osteoporosis]]). Common complications of toxic adenoma include [[atrial fibrillation]], neck compression, bone mineral loss, [[thyroid storm]], I-131-related [[hypothyroidism]]. [[Prognosis]] of toxic adenoma is generally good with treatment. About 45% to 75% of patients stay [[euthyroid]] following [[Iodine-131|I-131 therapy]].


==Natural History==
==Natural History==

Revision as of 16:05, 18 October 2017

Toxic Adenoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Toxic Adenoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Template:T On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Toxic Adenoma natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Toxic Adenoma natural history, complications and prognosis

CDC on Toxic Adenoma natural history, complications and prognosis

Toxic Adenoma natural history, complications and prognosis in the news

Blogs on Toxic Adenoma natural history, complications and prognosis

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Toxic Adenoma natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

If left untreated, some of the patients with toxic adenoma may progress to develop thyrotoxicosis which increases the risks of atrial fibrillation, heart failure, and decreased bone mineral density in postmenopausal women (osteoporosis). Common complications of toxic adenoma include atrial fibrillation, neck compression, bone mineral loss, thyroid storm, I-131-related hypothyroidism. Prognosis of toxic adenoma is generally good with treatment. About 45% to 75% of patients stay euthyroid following I-131 therapy.

Natural History

Complications

Complications of toxic adenoma are mainly due thyrotoxicosis which includes a constellation of symptoms and signs caused by excess circulating and tissue free triiodothyronine (T3 ), free thyroxine (T4 ), or both. These result in hypermetabolism and other excessive tissue-specific thyroid hormone effects. Common complications of toxic adenoma include:[3]

Prognosis

References

  1. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA (2001). "Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study". Lancet. 358 (9285): 861–5. doi:10.1016/S0140-6736(01)06067-6. PMID 11567699.
  2. Pearce EN, Braverman LE (2004). "Hyperthyroidism: advantages and disadvantages of medical therapy". Surg. Clin. North Am. 84 (3): 833–47. doi:10.1016/j.suc.2004.01.007. PMID 15145238.
  3. Ertek S, Cicero AF (2013). "Hyperthyroidism and cardiovascular complications: a narrative review on the basis of pathophysiology". Arch Med Sci. 9 (5): 944–52. doi:10.5114/aoms.2013.38685. PMC 3832836. PMID 24273583.
  4. Erdoğan MF, Küçük NO, Anil C, Aras S, Ozer D, Aras G, Kamel N (2004). "Effect of radioiodine therapy on thyroid nodule size and function in patients with toxic adenomas". Nucl Med Commun. 25 (11): 1083–7. PMID 15577585.
  5. Hegedüs L (2004). "Clinical practice. The thyroid nodule". N. Engl. J. Med. 351 (17): 1764–71. doi:10.1056/NEJMcp031436. PMID 15496625.